Table 2.
Cytotoxicity Data for Compounds 2 and 3a
| compound | cell lineb
|
||||
|---|---|---|---|---|---|
| NCI-H460 | SF-268 | MCF-7 | PC-3M | MDA-MB-231 | |
| 2 | 1.45 ± 0.09 | 1.41 ± 0.20 | 1.99 ± 0.12 | 1.71 ± 0.06 | 2.95 ± 0.40 |
| 3 | 3.57 ± 0.26 | 4.73 ± 0.33 | 3.98 ± 0.14 | 4.51 ± 0.37 | >5.0 |
| doxorubicin | 0.42 ± 0.30 | 0.62 ± 0.07 | 0.42 ± 0.13 | 0.24 ± 0.09 | 0.58 ± 0.23 |
a
Results are expressed as IC50 value ± standard deviation in μM. Doxorubicin and DMSO were used as positive and negative controls.
b
Key: NCI-H460 = human non-small-cell lung cancer; SF-268 = human CNS cancer (glioma); MCF-7 = human breast cancer; PC-3M = metastatic human prostate adenocarcinoma; MDA-MB-231 = metastatic human breast adenocarcinoma.